Cargando…

Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains

BACKGROUND: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Sagarika, Poore, Matthew, Gerdes, Svetlana, Nedveck, Derek, Lauridsen, Lene, Kristensen, Heidi Thomsen, Jensen, Henrik Max, Byrd, Phillip M., Ouwehand, Arthur C., Patterson, Elaine, Morovic, Wesley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419935/
https://www.ncbi.nlm.nih.gov/pubmed/34488774
http://dx.doi.org/10.1186/s12934-021-01658-4
_version_ 1783748858265731072
author Banerjee, Sagarika
Poore, Matthew
Gerdes, Svetlana
Nedveck, Derek
Lauridsen, Lene
Kristensen, Heidi Thomsen
Jensen, Henrik Max
Byrd, Phillip M.
Ouwehand, Arthur C.
Patterson, Elaine
Morovic, Wesley
author_facet Banerjee, Sagarika
Poore, Matthew
Gerdes, Svetlana
Nedveck, Derek
Lauridsen, Lene
Kristensen, Heidi Thomsen
Jensen, Henrik Max
Byrd, Phillip M.
Ouwehand, Arthur C.
Patterson, Elaine
Morovic, Wesley
author_sort Banerjee, Sagarika
collection PubMed
description BACKGROUND: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can affect host mental health outcomes. Understanding the molecular characteristics of GABA production by microbes within the gut can offer insight to novel therapies for mental health. RESULTS: Three strains of Levilactobacillus brevis with syntenous glutamate decarboxylase (GAD) operons were evaluated for overall growth, glutamate utilization, and GABA production in typical synthetic growth media supplemented with monosodium glutamate (MSG). Levilactobacillus brevis Lbr-6108™ (Lbr-6108), formerly known as L. brevis DPC 6108, and Levilactobacillus brevis Lbr-35 ™ (Lbr-35) had similar growth profiles but differed significantly in GABA secretion and acid resistance. Lbr-6108 produced GABA early within the growth phase and produced significantly more GABA than Lbr-35 and the type strain Levilactobacillus brevis ATCC 14869 after the stationary phase. The global gene expression during GABA production at several timepoints was determined by RNA sequencing. The GAD operon, responsible for GABA production and secretion, activated in Lbr-6108 after only 6 h of fermentation and continued throughout the stationary phase. Furthermore, Lbr-6108 activated many different acid resistance mechanisms concurrently, which contribute to acid tolerance and energy production. In contrast, Lbr-35, which has a genetically similar GAD operon, including two copies of the GAD gene, showed no upregulation of the GAD operon, even when cultured with MSG. CONCLUSIONS: This study is the first to evaluate whole transcriptome changes in Levilactobacillus brevis during GABA production in different growth phases. The concurrent expression of multiple acid-resistance mechanisms reveals niche-specific metabolic functionality between common human commensals and highlights the complex regulation of GABA metabolism in this important microbial species. Furthermore, the increased and rapid GABA production of Lbr-6108 highlights the strain’s potential as a therapeutic and the overall value of screening microbes for effector molecule output. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-021-01658-4.
format Online
Article
Text
id pubmed-8419935
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84199352021-09-09 Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains Banerjee, Sagarika Poore, Matthew Gerdes, Svetlana Nedveck, Derek Lauridsen, Lene Kristensen, Heidi Thomsen Jensen, Henrik Max Byrd, Phillip M. Ouwehand, Arthur C. Patterson, Elaine Morovic, Wesley Microb Cell Fact Research BACKGROUND: Of the many neurotransmitters in humans, gamma-aminobutyric acid (GABA) shows potential for improving several mental health indications such as stress and anxiety. The microbiota-gut-brain axis is an important pathway for GABAergic effects, as microbially-secreted GABA within the gut can affect host mental health outcomes. Understanding the molecular characteristics of GABA production by microbes within the gut can offer insight to novel therapies for mental health. RESULTS: Three strains of Levilactobacillus brevis with syntenous glutamate decarboxylase (GAD) operons were evaluated for overall growth, glutamate utilization, and GABA production in typical synthetic growth media supplemented with monosodium glutamate (MSG). Levilactobacillus brevis Lbr-6108™ (Lbr-6108), formerly known as L. brevis DPC 6108, and Levilactobacillus brevis Lbr-35 ™ (Lbr-35) had similar growth profiles but differed significantly in GABA secretion and acid resistance. Lbr-6108 produced GABA early within the growth phase and produced significantly more GABA than Lbr-35 and the type strain Levilactobacillus brevis ATCC 14869 after the stationary phase. The global gene expression during GABA production at several timepoints was determined by RNA sequencing. The GAD operon, responsible for GABA production and secretion, activated in Lbr-6108 after only 6 h of fermentation and continued throughout the stationary phase. Furthermore, Lbr-6108 activated many different acid resistance mechanisms concurrently, which contribute to acid tolerance and energy production. In contrast, Lbr-35, which has a genetically similar GAD operon, including two copies of the GAD gene, showed no upregulation of the GAD operon, even when cultured with MSG. CONCLUSIONS: This study is the first to evaluate whole transcriptome changes in Levilactobacillus brevis during GABA production in different growth phases. The concurrent expression of multiple acid-resistance mechanisms reveals niche-specific metabolic functionality between common human commensals and highlights the complex regulation of GABA metabolism in this important microbial species. Furthermore, the increased and rapid GABA production of Lbr-6108 highlights the strain’s potential as a therapeutic and the overall value of screening microbes for effector molecule output. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-021-01658-4. BioMed Central 2021-09-06 /pmc/articles/PMC8419935/ /pubmed/34488774 http://dx.doi.org/10.1186/s12934-021-01658-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Banerjee, Sagarika
Poore, Matthew
Gerdes, Svetlana
Nedveck, Derek
Lauridsen, Lene
Kristensen, Heidi Thomsen
Jensen, Henrik Max
Byrd, Phillip M.
Ouwehand, Arthur C.
Patterson, Elaine
Morovic, Wesley
Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
title Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
title_full Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
title_fullStr Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
title_full_unstemmed Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
title_short Transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (GABA) production in select Levilactobacillus brevis strains
title_sort transcriptomics reveal different metabolic strategies for acid resistance and gamma-aminobutyric acid (gaba) production in select levilactobacillus brevis strains
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419935/
https://www.ncbi.nlm.nih.gov/pubmed/34488774
http://dx.doi.org/10.1186/s12934-021-01658-4
work_keys_str_mv AT banerjeesagarika transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT poorematthew transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT gerdessvetlana transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT nedveckderek transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT lauridsenlene transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT kristensenheidithomsen transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT jensenhenrikmax transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT byrdphillipm transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT ouwehandarthurc transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT pattersonelaine transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains
AT morovicwesley transcriptomicsrevealdifferentmetabolicstrategiesforacidresistanceandgammaaminobutyricacidgabaproductioninselectlevilactobacillusbrevisstrains